The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes.

Postprandial hyperglycemia and preprandial hypoglycemia contribute to poor glycemic control in type 1 diabetes. We hypothesized that postprandial glycemic excursions could be normalized in type 1 diabetes by suppressing glucagon with pramlintide acetate in the immediate postprandial period and supplementing glucagon in the late postprandial period. A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus-to-carbohydrate ratio during a standard liquid meal. Type 1 diabetic subjects were then randomized to two open-labeled studies. On one occasion, type 1 diabetic subjects received a 60% increase in the insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30-45 microg pramlintide with their usual insulin bolus-to-carbohydrate ratio. Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min. The plasma glucose area under the curve (AUC) for 0-420 min was lower in control versus type 1 diabetic subjects (316 +/- 5 vs. 929 +/- 18 mg x h(-1) x dl(-1), P < 0.0001). Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC(0-180 min) 470 +/- 43 vs. 434 +/- 48 mg x h(-1) x dl(-1), P < 0.01). Pramlintide administration suppressed glucagon (P < 0.02), and glucagon injections prevented late hypoglycemia with increased insulin. In summary, in type 1 diabetes, glucagon modulation with pramlintide as an adjunct to insulin therapy may prove beneficial in controlling postmeal glycemic swings.

[1]  R. Unger,et al.  The role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus. , 1975, Metabolism: clinical and experimental.

[2]  R. Rizza,et al.  Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. , 1984, The Journal of clinical investigation.

[3]  W. Tamborlane,et al.  Exaggerated epinephrine responses to hypoglycemia in normal and insulin-dependent diabetic children. , 1987, Jornal de Pediatria.

[4]  P. Cryer,et al.  Hypoglycemia in IDDM , 1989, Diabetes.

[5]  W. Tamborlane,et al.  Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. , 1991, The Journal of clinical endocrinology and metabolism.

[6]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[7]  D. A. Trainor,et al.  Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. , 1996, Clinical chemistry.

[8]  T. Jones,et al.  Incidence and predictive criteria of nocturnal hypoglycemia in young children with insulin-dependent diabetes mellitus. , 1997, The Journal of pediatrics.

[9]  J. Mullane,et al.  Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial , 1997, Diabetes.

[10]  M. Denaro,et al.  Roles of amylin in diabetes and in regulation of nutrient load. , 1998, Nutrition.

[11]  K. Alberti,et al.  The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. , 1999, Metabolism: clinical and experimental.

[12]  H. M. Rizor,et al.  All Our Patients Need to Know About Intensified Diabetes Management They Learned in Fourth Grade , 2000, The Diabetes educator.

[13]  W. Tamborlane,et al.  Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. , 2001, Diabetes care.

[14]  W. Tamborlane,et al.  Recent advances in treatment of youth with Type 1 diabetes: better care through technology , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[15]  M. Haymond,et al.  Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. , 2001, Diabetes care.

[16]  C. Weyer,et al.  A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. , 2002, Diabetes care.

[17]  M. Rewers,et al.  Predictors of acute complications in children with type 1 diabetes. , 2002, JAMA.

[18]  L. Want,et al.  Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. , 2002, Diabetes technology & therapeutics.

[19]  A. Zinsmeister,et al.  Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus , 2002, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[20]  C. Weyer,et al.  Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone. , 2002, Diabetes technology & therapeutics.

[21]  C. Weyer,et al.  The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[22]  C. Weyer,et al.  Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. , 2003, Metabolism: clinical and experimental.

[23]  G. Steil,et al.  Modeling beta-cell insulin secretion--implications for closed-loop glucose homeostasis. , 2003, Diabetes technology & therapeutics.

[24]  C. Weyer,et al.  Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets , 2003, Diabetes, obesity & metabolism.

[25]  T. Jones,et al.  The impact of a decade of changing treatment on rates of severe hypoglycemia in a population-based cohort of children with type 1 diabetes. , 2004, Diabetes care.

[26]  G. Steil,et al.  Closed-loop insulin delivery-the path to physiological glucose control. , 2004, Advanced drug delivery reviews.

[27]  S. Schwartz,et al.  Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM , 1996, Diabetologia.

[28]  Kiyoshi Yamaoka,et al.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations , 1978, Journal of Pharmacokinetics and Biopharmaceutics.